Navigation Links
Digital communication technology helps clear path to personalized therapies
Date:1/9/2009

LA JOLLA, Calif., January 9, 2009 -- Researchers at the Burnham Institute for Medical Research (Burnham) have shown that search algorithms used in digital communications can help scientists identify effective multi-drug combinations. The study, led by Giovanni Paternostro, M.D., Ph.D., was published in the December 26, 2008, issue of PLoS Computational Biology.

Using the stack sequential algorithm, which was developed for digital communications, the team of scientists searched for optimal drug combinations. This algorithm can integrate information from different sources, including biological measurements and model simulations. This differs from the classic systems biology approach by having search algorithms rather than explicit quantitative models as the central element. The variability of biological systems is the fundamental motivation for this strategy.

"Combination therapies have demonstrated efficacy in treating complex diseases such as cancer and hypertension, but it is difficult to identify safe and effective combination treatment regimens using only trial and error," said Dr. Paternostro. "As personalized medicine moves from the present emphasis on diagnosis and prognosis to therapy, the problem of searching for optimal drug combinations uniquely suited to the genetic and molecular profile of each patient will need to be solved. This research is a first step in that direction."

Current methodology for identifying effective combination therapies involves exhaustive testing. However, the exponential expansion of possibilities precludes exploring large combinations using this approach. For example, many chemotherapy regimens include six drugs from a pool of 100. A study that included all combinations (including partial combinations containing only some of these compounds) at three different doses would have to digest 8.9 x 10^11 possibilities. The problem requires a new approach rather than more efficient screening technology.

In the study, a small subset of the possible drug combinations identified using the algorithms were tested in two biological model systems. One system studied improvement in the physiological decline associated with aging in Drosophila melanogaster (fruit flies) and the other system tested for selective killing of cancer cells. In both cases, effective drug combinations were identified by combining the algorithm with biological tests.

"Our work was greatly helped by collaborators with expertise in medicine, engineering and physics from Burnham, University of California, San Diego and Michigan State University," said Dr Paternostro. "We especially benefited from suggestions from Dr. Andrew Viterbi, inventor of the Viterbi algorithm so widely used in digital communications, who pointed to parallels between this biological problem and signal decoding." Dr. Andrew Viterbi cofounded Linkabit Corporation and Qualcomm Inc., with Dr. Irwin Jacobs. He is currently the president of the venture capital firm, The Viterbi Group.


'/>"/>

Contact: Josh Baxt
jbaxt@burnham.org
858-795-5236
Burnham Institute
Source:Eurekalert

Related biology news :

1. Entrust Digital Signatures Help Secure More Than 18 Million U.S. ePassports
2. Book is the first high-resolution digital mouse brain atlas designed for Web applications
3. FEBS Letters Structured Digital Abstracts experiment
4. Vobile Launches VideoDNA Live; Enables Real-Time Digital Content Protection for Live Broadcast Events
5. Fixing the education digital disconnect one video game at a time
6. Digital cameras, remote satellites measure crop water demand
7. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
8. DigitalPersona Places Identity Protection at Peoples Fingertips
9. The birds of Spain, in a digital ornithological encyclopedia
10. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
11. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... As Outsourcing of Cell Line Development Services Drives the ... by Expanding their Service Portfolio and Collaborating with Biopharmaceutical ... cell banking market addresses market sizing, emerging trends, and ... in the market. The base year considered is 2015 ... The cell banking market is expected to grow ...
(Date:1/24/2017)... ORANGE COUNTY, Calif. , Jan. 24, 2017 ... respiratory testing solutions, announced today that in ... providing advanced respiratory assessment to the Roche FIREFISH ... muscular atrophy (SMA) develop respiratory insufficiency due to ... alpha motor neurons in the spinal cord. This ...
(Date:1/24/2017)... Reha Technology USA Inc. has ... . The need for Robotic technology in the rehab space ... in the surgical space. Project Walk – Boston ... and adding technology to their continuum of care. They now have ... repetitions which has been shown to improve gait with patients. The ...
(Date:1/24/2017)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... nervous system (CNS) diseases, is pleased to announce that ... with the U.S. Food and Drug Administration (FDA), a ... LevoCap ER (REL-1015, levorphanol extended release, abuse deterrent capsules) ... filing is achievable.   "The FDA,s input ...
Breaking Biology Technology: